FDMT vs CGON โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGON Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Momentum & Technical, Options & Structure while FDMT counters with relative strength in Growth & Margin. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | CGON Revenue | FDMT Op. Margin | CGON Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -729.4% | N/A | FDMT |
| FY2020 | $10M | N/A | -424.0% | N/A | FDMT |
| FY2021 | $20M | N/A | -395.5% | N/A | FDMT |
| FY2022 | $0M | N/A | -3516.5% | N/A | FDMT |
| FY2023 | $20M | $0M | -544.6% | -27180.9% | FDMT |
| FY2024 | $0M | $0M | -507678.4% | -10067.3% | CGON |
| FY2025 | $90M | $0M | -187.2% | -4722.1% | FDMT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FDMT | CGON | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $669.3M | $6.3B | Larger Scale | CGON |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +4505.6% | -3.7% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -222.7% | -4293.5% | Higher Margin | FDMT |
| Net Profit Margin Profitability | -208.6% | 0.0% | Higher Margin | CGON |
| Return on Equity (ROE) Capital Efficiency | -56.7% | -28.3% | Higher ROE | CGON |
| 52-Week Range Position Momentum | 47% ($7โ$17) | 84% ($37โ$94) | Stronger Trend | CGON |
| Beta / 30D Volatility Risk Regime | 1.89ฮฒ ยท 90% Vol | 0.75ฮฒ ยท 89% Vol | Lower Realized Risk | CGON |
| Unified Institutional Score Composite Signal | 51.3 / 100 (HOLD) | 45.0 / 100 (HOLD) | Higher Composite | FDMT |